DOCSLIB.ORG

PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev Harmonized Tariff Schedule of the United States (2008) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE 77337-76-9 ACOTIAMIDUM 185106-16-5 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7 ACRIFLAVINIUM CHLORIDE 8063-24-9 ACEBUTOLOL 37517-30-9 ACRIHELLIN 67696-82-6 ACECAINIDE 32795-44-1 ACRISORCIN 7527-91-5 ACECARBROMAL 77-66-7 ACRIVASTINE 87848-99-5 ACECLIDINE 827-61-2 ACROCINONIDE 28971-58-6 ACECLOFENAC 89796-99-6 ACRONINE 7008-42-6 ACEDAPSONE 77-46-3 ACTAGARDIN ACEDIASULFONE SODIUM 127-60-6 ACTAPLANIN 37305-75-2 ACEDOBEN 556-08-1 ACTARIT 18699-02-0 ACEFLURANOL 80595-73-9 ACTINOQUINOL 15301-40-3 ACEFURTIAMINE 10072-48-7 ACTISOMIDE 96914-39-5 ACEFYLLINE CLOFIBROL 70788-27-1 ACTODIGIN 36983-69-4 ACEFYLLINE PIPERAZINE 18428-63-2 ADAFENOXATE 82168-26-1 ACEGLATONE 642-83-1 ADALIMUMABUM 331731-18-1 ACEGLUTAMIDE 2490-97-3 ADAMEXINE 54785-02-3 ACEMANNAN 110042-95-0 ADAPALENE 106685-40-9 ACEMETACIN 53164-05-9 ADAPROLOL 101479-70-3 ACENEURAMIC ACID 131-48-6 ADARGILEUKINUM ALFA 250710-65-7 ACENOCOUMAROL 152-72-7 ADATANSERIN 127266-56-2 ACEPERONE 807-31-8 ADECATUMUMABUM 503605-66-1 ACEPROMAZINE 61-00-7 ADEFOVIR 106941-25-7 ACEPROMETAZINE 13461-01-3 ADEKALANTUM 227940-00-3 ACEQUINOLINE 42465-20-3 ADELMIDROL 1675-66-7 ACESULFAME 33665-90-6 ADEMETIONINE 17176-17-9 ACETAMINOSALOL 118-57-0 ADENOSINE PHOSPHATE 61-19-8 ACETARSOL 97-44-9 ADIBENDAN 100510-33-6 ACETAZOLAMIDE 59-66-5 ADICILLIN 525-94-0 ACETERGAMINE 3031-48-9 ADIMOLOL 78459-19-5 ACETIAMINE 299-89-8 ADINAZOLAM 37115-32-5 ACETIROMATE 2260-08-4 ADIPHENINE 64-95-9 ACETOHEXAMIDE 968-81-0 ADIPIODONE 606-17-7 ACETOHYDROXAMIC ACID 546-88-3 ADITEREN 56066-19-4 ACETOPHENAZINE 2751-68-0 ADITOPRIM 56066-63-8 ACETORPHINE 25333-77-1 ADOSOPINE 88124-26-9 ACETRYPTINE 3551-18-6 ADOZELESIN 110314-48-2 ACETYLCHOLINE CHLORIDE 60-31-1 ADRAFINIL 63547-13-7 ACETYLCYSTEINE 616-91-1 ADRENALONE 99-45-6 ACETYLDIGITOXIN 1111-39-3 ADROGOLIDUM 171752-56-0 ACETYLLEUCINE 99-15-0 AFALANINE 2901-75-9 ACETYLMETHADOL 509-74-0 AFELETECANUM 215604-75-4 ACEVALTRATE 25161-41-5 AFELIMOMAB 156227-98-4 ACEXAMIC ACID 57-08-9 AFLOQUALONE 56287-74-2 ACICLOVIR 59277-89-3 AFOVIRSEN 151356-08-0 ACIDUM ARUNDICUM 185517-21-9 AFUROLOL 65776-67-2 ACIDUM CALOXETICUM 135306-78-4 AGALSIDASUM ALFA 104138-64-9 ACIDUM CARGLUMICUM 1188-38-1 AGALSIDASUM BETA 104138-64-9 AGANODINE 86696-87-9 ALMOXATONE 84145-89-1 AGLEPRISTONE 124478-60-0 ALMURTIDE 61136-12-7 AGOMELATINE 138112-76-2 ALNESPIRONE 138298-79-0 AKLOMIDE 3011-89-0 ALNIDITAN 152317-89-0 ALACEPRIL 74258-86-9 ALONACIC 105292-70-4 ALAFOSFALIN 60668-24-8 ALONIMID 2897-83-8 ALAGEBRIUM CHLORIDUM 341028-37-3 ALORACETAM 119610-26-3 ALAMIFOVIRUM 193681-12-8 ALOSETRON 122852-42-0 ALANINE 56-41-7 ALOVUDINE 25526-93-6 ALANOSINE 5854-93-3 ALOXIPRIN 9014-67-9 ALAPROCLATE 60719-82-6 ALOXISTATIN 88321-09-9 ALATROFLOXACIN 157182-32-6 ALOZAFONE 65899-72-1 ALAZANINE TRICLOFENATE 5779-59-9 ALPERTINE 27076-46-6 ALBACONAZOLUM 187949-02-6 ALPHACETYLMETHADOL 17199-58-5 ALBENDAZOLE 54965-21-8 ALPHAMEPRODINE 468-51-9 ALBENDAZOLE OXIDE 54029-12-8 ALPHAMETHADOL 17199-54-1 ALBIFYLLINE 107767-55-5 ALPHAPRODINE 77-20-3 ALBUTOIN 830-89-7 ALPIDEM 82626-01-5 ALCLOFENAC 22131-79-9 ALPIROPRIDE 81982-32-3 ALCLOMETASONE 67452-97-5 ALPRAFENONE 124316-02-5 ALCLOXA 1317-25-5 ALPRAZOLAM 28981-97-7 ALCURONIUM CHLORIDE 15180-03-7 ALPRENOLOL 13655-52-2 ALDESULFONE SODIUM 144-75-2 ALPROSTADIL 745-65-3 ALDIOXA 5579-81-7 ALRESTATIN 51411-04-2 ALDOSTERONE 52-39-1 ALSACTIDE 34765-96-3 ALEFACEPTUM 222535-22-0 ALTANSERIN 76330-71-7 ALEMCINALUM 150785-53-8 ALTAPIZONE 93277-96-4 ALEMTUZUMABUM 216503-57-0 ALTECONAZOLE 93479-96-0 ALENDRONIC ACID 66376-36-1 ALTEPLASE 105857-23-6 ALENTEMOL 112891-97-1 ALTINICLINUM 179120-92-4 ALEPRIDE 66564-15-6 ALTIZIDE 5588-16-9 ALESTRAMUSTINE 139402-18-9 ALTOQUALINE 121029-11-6 ALEXIDINE 22573-93-9 ALTRENOGEST 850-52-2 ALEXITOL SODIUM 66813-51-2 ALTRETAMINE 645-05-6 ALFACALCIDOL 41294-56-8 ALTUMOMAB 156586-92-4 ALFADEX 10016-20-3 ALUMINIUM CLOFIBRATE 24818-79-9 ALFADOLONE 14107-37-0 ALUSULF 61115-28-4 ALFAPROSTOL 74176-31-1 ALVAMELINUM 120241-31-8 ALFATRADIOLUM 57-91-0 ALVERINE 150-59-4 ALFAXALONE 23930-19-0 ALVIMOPANUM 156053-89-3 ALFENTANIL 71195-58-9 ALVIRCEPT SUDOTOX 137487-62-8 ALFETAMINE 4255-23-6 ALVOCIDIBUM 146426-40-6 ALFIMEPRASUM 259074-76-5 AMADINONE 30781-27-2 ALFUZOSIN 81403-80-7 AMAFOLONE 50588-47-1 ALGELDRATE 1330-44-5 AMANOZINE 537-17-7 ALGESTONE 595-77-7 AMANTADINE 768-94-5 ALGLUCERASE 143003-46-7 AMANTANIUM BROMIDE 58158-77-3 ALGLUCOSIDASUM ALFA 420784-05-0 AMANTOCILLIN 10004-67-8 ALIBENDOL 26750-81-2 AMBAMUSTINE 85754-59-2 ALICAFORSENUM 185229-68-9 AMBASILIDE 83991-25-7 ALICONAZOLE 63824-12-4 AMBAZONE 539-21-9 ALIFEDRINE 78756-61-3 AMBENONIUM CHLORIDE 115-79-7 ALIFLURANE 56689-41-9 AMBENOXAN 2455-84-7 ALILUSEMUM 144506-11-6 AMBICROMIL 58805-38-2 ALIMADOL 52742-40-2 AMBOMYCIN 1402-81-9 ALIMEMAZINE 84-96-8 AMBRISENTANUM 177036-94-1 ALINASTINE 154541-72-7 AMBROXOL 18683-91-5 ALINIDINE 33178-86-8 AMBRUTICIN 58857-02-6 ALIPAMIDE 3184-59-6 AMBUCAINE 119-29-9 ALISKIRENUM 173334-57-1 AMBUCETAMIDE 519-88-0 ALITRETINOINUM 5300-03-8 AMBUSIDE 3754-19-6 ALIZAPRIDE 59338-93-1 AMCINAFAL 3924-70-7 ALLETORPHINE 23758-80-7 AMCINAFIDE 7332-27-6 ALLOBARBITAL 52-43-7 AMCINONIDE 51022-69-6 ALLOCLAMIDE 5486-77-1 AMDOXOVIRUM 145514-04-1 ALLOCUPREIDE SODIUM 5965-40-2 AMEBUCORT 83625-35-8 ALLOMETHADIONE 526-35-2 AMEDALIN 22136-26-1 ALLOPURINOL 315-30-0 AMEDIPLASUM 151912-11-7 ALLYLESTRENOL 432-60-0 AMELOMETASONE 123013-22-9 ALLYLPRODINE 25384-17-2 AMELTOLIDE 787-93-9 ALLYLTHIOUREA 109-57-9 AMELUBANTUM 346735-24-8 ALMADRATE SULFATE 60239-66-9 AMESERGIDE 121588-75-8 ALMAGATE 66827-12-1 AMETANTRONE 64862-96-0 ALMAGODRATE AMEZEPINE 60575-32-8 ALMASILATE 71205-22-6 AMEZINIUM METILSULFATE 30578-37-1 ALMECILLIN 87-09-2 AMFEBUTAMONE 34911-55-2 ALMESTRONE 10448-96-1 AMFECLORAL 5581-35-1 ALMINOPROFEN 39718-89-3 AMFENAC 51579-82-9 ALMITRINE 27469-53-0 AMFEPENTOREX 15686-27-8 ALMOKALANT 123955-10-2 AMFEPRAMONE 90-84-6 ALMOTRIPTAN 154323-57-6 AMFETAMINE 300-62-9 Harmonized Tariff Schedule of the United States (2008) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 AMFETAMINIL 17590-01-1 AMPICILLIN 69-53-4 AMFLUTIZOLE 82114-19-0 AMPIROXICAM 99464-64-9 AMFOMYCIN 1402-82-0 AMPRENAVIRUM 161814-49-9 AMFONELIC ACID 15180-02-6 AMPROLIUM 121-25-5 AMICARBALIDE 3459-96-9 AMPYRIMINE 5587-93-9 AMICIBONE 23271-63-8 AMPYZINE 5214-29-9 AMICYCLINE 5874-95-3 AMQUINATE 17230-85-2 AMIDANTEL 49745-00-8 AMRINONE 60719-84-8 AMIDAPSONE 3569-77-5 AMRUBICIN 110267-81-7 AMIDEFRINE MESILATE 1421-68-7 AMSACRINE 51264-14-3 AMIFLAMINE 77518-07-1 AMTOLMETIN GUACIL 87344-06-7 AMIFLOVERINE 54063-24-0 AMYLMETACRESOL 1300-94-3 AMIFLOXACIN 86393-37-5 ANAGESTONE 2740-52-5 AMIFOSTINE 20537-88-6 ANAGRELIDE 68475-42-3 AMIGLUMIDUM 119363-62-1 ANAKINRA 143090-92-0 AMIKACIN 37517-28-5 ANARITIDE 95896-08-5 AMIKHELLINE 4439-67-2 ANASTROZOLE 120511-73-1 AMILORIDE 2609-46-3 ANATIBANTUM 209733-45-9 AMINDOCATE 31386-24-0 ANATUMOMABUM MAFENATOXUM (NONE) AMINEPTINE 57574-09-1 ANAXIRONE 77658-97-0 AMINITROZOLE 140-40-9 ANAZOCINE 15378-99-1 AMINOACRIDINE 90-45-9 ANAZOLENE SODIUM 3861-73-2 AMINOCAPROIC ACID 60-32-2 ANCAROLOL 75748-50-4 AMINOETHYL NITRATE 646-02-6 ANCESTIMUM 163545-26-4 AMINOGLUTETHIMIDE 125-84-8 ANCITABINE 31698-14-3 AMINOMETRADINE 642-44-4 ANCRIVIROCUM 370893-06-4 AMINOPHENAZONE 58-15-1 ANCROD 9046-56-4 AMINOPHENAZONE CYCLAMATE 747-30-8 ANDOLAST 132640-22-3 AMINOPHYLLINE 317-34-0 ANDROSTANOLONE 521-18-6 AMINOPROMAZINE 58-37-7 ANECORTAVUM 7753-60-8 AMINOPTERIN SODIUM 58602-66-7 ANGIOTENSIN II 4474-91-3 AMINOQUINOL 10023-54-8 ANGIOTENSINAMIDE 53-73-6 AMINOQUINURIDE 3811-56-1 ANIDOXIME 34297-34-2 AMINOREX 2207-50-3 ANIDULAFUNGINUM 166663-25-8 AMINOTHIAZOLE 96-50-4 ANILAMATE 5591-49-1 AMINOXYTRIPHENE 5585-64-8 ANILERIDINE 144-14-9 AMIODARONE 1951-25-3 ANILOPAM 53716-46-4 AMIPERONE 1580-71-8 ANIPAMIL 83200-10-6 AMIPHENAZOLE 490-55-1 ANIRACETAM 72432-10-1 AMIPIZONE 69635-63-8 ANIROLAC 66635-85-6 AMIPRILOSE 56824-20-5 ANISACRIL 5129-14-6 AMIQUINSIN 13425-92-8 ANISINDIONE
Load more

Recommended publications
  • The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus Cyanogenys
    W&M ScholarWorks Dissertations, Theses, and Masters Projects Theses, Dissertations, & Master Projects 1970 The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus cyanogenys William F. McConnell College of William & Mary - Arts & Sciences Follow this and additional works at: https://scholarworks.wm.edu/etd Part of the Physiology Commons Recommended Citation McConnell, William F., "The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus cyanogenys" (1970). Dissertations, Theses, and Masters Projects. Paper 1539624685. https://dx.doi.org/doi:10.21220/s2-1smx-cy32 This Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Dissertations, Theses, and Masters Projects by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. THE INFLUENCE OF HYPOTHALAMIC STEROID IMPLANTS ON OVULATION AND OVARIAN GROWTH AND FUNCTION IN THE IGUANID LIZARD, SCELOPORUS CYANOGENYS A Thesis Presented to The Faculty of the Department of Biology The College of William and Mary in Virginia In Partial Fulfillment Of the Requirements for the Degree of Master of Arts By William F. McConnell 1970 ProQuest Number: 10625114 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.
    [Show full text]
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Guidelines for NON - CRITICAL CARE Staff Common Vasoactive Drugs These Drugs Are Used to Maintain Cardiovascular Stability
    Guidelines for NON - CRITICAL CARE staff Common vasoactive drugs These drugs are used to maintain cardiovascular stability. The full guide to administration can be found on BSUH infonet > intensive care unit > clinical guidelines > inotropes These drugs MUST be given via a central venous catheter. Be given via a ‘dedicated’ line (several vasoactives can run together in one lumen of a CVC) with a 2, 3 or 4 lumen connector. given via an ICU specific syringe driver – these allow you to change the rate without pausing the infusion. All ICU pumps have ICU or HDU spray-painted on them. Be ‘double pumped’ ie: when changing syringe, the old and new infusions run concurrently to prevent loss of infusion during change UNLESS ‘RAPID CHANGE- OVER’ TECHNIQUE IS USED, DUE TO LACK OF AVAILABLE PUMPS These drugs MUST NOT be paused, stopped or disconnected suddenly – they have a short half-life and pausing/stopping/disconnection may cause rapid CVS deterioration or arrest UNLESS ‘RAPID CHANGE-OVER’ TECHNIQUE IS USED, DUE TO LACK OF AVAILABLE PUMPS be given as a bolus, or bolused via the pump – this could cause rapid CVS instability run with ANY drug other than a vasoactive drug COMMON VASOACTIVES NORADRENALINE – vasopressor: causes vasoconstriction and used to improve BP USES: sepsis, septic shock, severe hypotension not resolved with fluid ADRENALINE – inotrope: increases contractility, raises BP and HR USES: sepsis, septic shock, severe bradycardia DOBUTAMINE – intrope and vasodilator: increases contractility and reduces cardiac work USES:
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Supplementary Information D41586-018-05049-5
    COMMENT Supplementary information to: When will clinical trials finally reflect diversity? To accompany a Comment published in Nature 557, 157–159 (2018) https://www.nature.com/articles/d41586-018-05049-5 by Todd C. Knepper & Howard L. McLeod SUPPLEMENTARY INFORMATION | NATURE | 1 Supplementary Tables Supplementary Table 1. List of drugs included in analysis Year Trade Name Non-Proprietary name Area Chemical Type Approved Gabitril tiagabine 1997 CNS 1 - New molecular entity (NME) Mirapex pramipexol 1997 CNS 1 - New molecular entity (NME) Requip ropinorole 1997 CNS 1 - New molecular entity (NME) Seroquel quetiapine 1997 CNS 1 - New molecular entity (NME) Zomig zolmitriptan 1997 CNS 1 - New molecular entity (NME) Apokyn apomorphine 2004 CNS 1 - New molecular entity (NME) Cymbalta duloxetine 2004 CNS 1 - New molecular entity (NME) Lunesta eszopiclone 2004 CNS 1 - New molecular entity (NME) Lyrica pregabalin 2004 CNS 1 - New molecular entity (NME) Prialt ziconotide 2004 CNS 1 - New molecular entity (NME) Tysabri natalizumab 2004 CNS BLA Fanapt ilioperidone 2009 CNS 1 - New molecular entity (NME) Saphris asenapine 2009 CNS 1 - New molecular entity (NME) Savella milnacipran 2009 CNS 1 - New molecular entity (NME) Amyvid florbetapir F 18 2012 CNS 1 - New molecular entity (NME) Aubagio teriflunomide 2012 CNS 1 - New molecular entity (NME) Fycompa perampanel 2012 CNS 1 - New molecular entity (NME) Belsomra suvarxant 2014 CNS 1 - New molecular entity (NME) Hetlioz tasimelteon 2014 CNS 1 - New molecular entity (NME) Movantik naloxegol 2014 CNS 1
    [Show full text]
  • Wednesday, July 10, 2019 4:00Pm
    Wednesday, July 10, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – July 10, 2019 DATE: July 3, 2019 NOTE: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the July meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – Appendix B Action Item – Vote to Prior Authorize Jornay PM™ [Methylphenidate Extended-Release (ER) Capsule], Evekeo ODT™ [Amphetamine Orally Disintegrating Tablet (ODT)], Adhansia XR™ (Methylphenidate ER Capsule), and Sunosi™ (Solriamfetol Tablet) – Appendix C Action Item – Vote to Prior Authorize Balversa™ (Erdafitinib) – Appendix D Action Item – Vote to Prior Authorize Annovera™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System), Bijuva™ (Estradiol/Progesterone Capsule), Cequa™ (Cyclosporine 0.09% Ophthalmic Solution), Corlanor® (Ivabradine Oral Solution), Crotan™ (Crotamiton 10% Lotion), Gloperba® (Colchicine Oral Solution), Glycate® (Glycopyrrolate Tablet), Khapzory™ (Levoleucovorin Injection), Qmiiz™ ODT [Meloxicam Orally Disintegrating Tablet (ODT)], Seconal Sodium™ (Secobarbital
    [Show full text]